Diagnosis and monitoring of HIV-1 group o-infected patients in cameroun

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 1, 2010, Pages 107-110

  Vessière, Aurélia ^a   Rousset, Dominique ^a   Kfutwah, Anfumbom ^a   Leoz, Marie ^a   Depatureaux, Agnès ^b   Simon, François ^c   Plantier, Jean Christophe ^b  

^a CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^b HÔPITAL CHARLES NICOLLE   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Cameroun; Genotypic resistance; HIV 1 group O; Serological algorithm; Viral monitoring

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; ZIDOVUDINE;

ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; CAMEROON; CONTROLLED STUDY; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST; SEROTYPING; STRUCTURAL GENE; VIRUS DETECTION; VIRUS GENE; VIRUS LOAD;

ALGORITHMS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENES, ENV; GENES, POL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PYRIDINES; PYRONES; SAQUINAVIR; VIRAL LOAD;

EID: 74049090141     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b97ec1     Document Type: Article

References (16)

1. Quinones-Mateu ME, Ball SC, Arts EJ. Role of human immunodeficiency virus type 1 group O in the AIDS pandemic. AIDS Rev. 2000;2:190-202.
2. Ayouba A, Mauclère P, Martin PMV, et al. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg Infect Dis. 2001;7:466-467.
3. Vergne L, Bourgeois A, Mpoudi-Ngole E, et al. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02-AG variant and disease stage. Virology. 2003;310: 254-266.
4. Zouhair S, Roussin-Bretagne S, Moreau A, et al. Group O human immunodeficiency virus type 1 infection that escaped detection in two immunoassays. J Clin Microbiol. 2006;44:662-665.
5. Henquell C, Jacomet C, Antoniotti O, et al. Difficulties in diagnosing group O human immunodeficiency virus type 1 acute primary infection. J Clin Microbiol. 2008;46:2453-2456.
6. Gautheret-Dejean A, Mesmin-Poho S, Birguel J, et al. Unequal detection of HIV type 1 group O infection by simple rapid tests. Clin Infect Dis. 2008;46:1936-1937.
7. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol. 1997;71:8893-8898.
8. Plantier JC, Leoz M, Depatureaux A, et al. Current resistance algorithms are not useful for HIV-1 group O-infected patients monitoring. Presented at: IV International AIDS Conference; July 22-25, 2007; Sydney, Australia.
9. Simon F, Souquière S, Damond F, et al. Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses. 2001;17:937-952.
10. Mauclere P, Damond F, Apetrei C, et al. Synthetic peptide ELISAs for detection of and discrimination between group M and group O HIV type 1 infection. AIDS Res Hum Retroviruses. 1997;13:987-993.
11. Gueudin M, Lemee V, Ferre V, et al. Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O. J Acquir Immune Defic Syndr. 2004;36:639-641.
12. Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr. 2007;45:380-388.
13. Chinnadurai R, Munch J, Dittmar MT, et al. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS. 2005;19:1919-1922.
14. Ariën KK, Abraha A, Quinones-Mateu ME, et al. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 Group O, and HIV-2 isolates. J Virol. 2005;79:8979-8990.
15. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994;265: 1587-1590.
16. Chaix-Baudier ML, Chappey C, Burgard M, et al. First case of mother-to-infant HIV type 1 group O transmission and evolution of C2V3 sequences in the infected child. French HIV Pediatric Cohort Study Group. AIDS Res Hum Retroviruses. 1998;14:15-23.